1 / 14

Aarkstore - Peregrine Pharmaceuticals, Inc. - Product Pipeli

Peregrine Pharmaceuticals, Inc. - Product Pipeline Review - 2014’, provides an overview of the Peregrine Pharmaceuticals, Inc.’s pharmaceutical research and development focus.

addyparker2350
Download Presentation

Aarkstore - Peregrine Pharmaceuticals, Inc. - Product Pipeli

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Category : Pharmaceuticals & Healthcare Peregrine Pharmaceuticals, Inc. - Product Pipeline Review - 2014 Browse Complete Report - http://www.aarkstore.com/pharmaceuticals-healthcare/63685/peregrine-pharmaceuticals-inc-product-pipeline-review

  2. Peregrine Pharmaceuticals, Inc. - Product Pipeline Review - 2014

  3. Summary Global Markets Direct’s, ‘Peregrine Pharmaceuticals, Inc. - Product Pipeline Review - 2014’, provides an overview of the Peregrine Pharmaceuticals, Inc.’s pharmaceutical research and development focus.  This report provides comprehensive information on the current therapeutic developmental pipeline of Peregrine Pharmaceuticals, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. “Peregrine Pharmaceuticals, Inc. - Product Pipeline Review - 2014”report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

  4. Summary Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

  5. Scope - The report provides brief overview of Peregrine Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Peregrine Pharmaceuticals, Inc.’s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Peregrine Pharmaceuticals, Inc.’s pipeline products

  6. Reasons to buy - Evaluate Peregrine Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Peregrine Pharmaceuticals, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Peregrine Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Peregrine Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Peregrine Pharmaceuticals, Inc.

  7. Table of Content List of Tables 3List of Figures 4Peregrine Pharmaceuticals, Inc. Snapshot 5Peregrine Pharmaceuticals, Inc. Overview 5Key Information 5Key Facts 5Peregrine Pharmaceuticals, Inc. - Research and Development Overview 6Key Therapeutic Areas 6Peregrine Pharmaceuticals, Inc. - Pipeline Review 9Pipeline Products by Stage of Development 9Pipeline Products - Monotherapy 10Pipeline Products - Partnered Products 11Partnered Products/Combination Treatment Modalities 12Pipeline Products - Out-Licensed Products 13

  8. Table of Content Out-Licensed Products/Combination Treatment Modalities 14Peregrine Pharmaceuticals, Inc. - Pipeline Products Glance 15Peregrine Pharmaceuticals, Inc. - Late Stage Pipeline Products 15Phase III Products/Combination Treatment Modalities 15Peregrine Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 16Phase II Products/Combination Treatment Modalities 16Phase I Products/Combination Treatment Modalities 17Peregrine Pharmaceuticals, Inc. - Early Stage Pipeline Products 18Preclinical Products/Combination Treatment Modalities 18Discovery Products/Combination Treatment Modalities 19Peregrine Pharmaceuticals, Inc. - Drug Profiles 20bavituximab 20

  9. List Of Tables Peregrine Pharmaceuticals, Inc., Key Information 5Peregrine Pharmaceuticals, Inc., Key Facts 5Peregrine Pharmaceuticals, Inc. - Pipeline by Indication, 2014 8Peregrine Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 9Peregrine Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 10Peregrine Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2014 11Peregrine Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 12Peregrine Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2014 13Peregrine Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014 14Peregrine Pharmaceuticals, Inc. - Phase III, 2014 15Peregrine Pharmaceuticals, Inc. - Phase II, 2014 16Peregrine Pharmaceuticals, Inc. - Phase I, 2014 17

  10. List of Figures Peregrine Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2014 7Peregrine Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 9Peregrine Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 10Peregrine Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2014 11Peregrine Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2014 13Peregrine Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2014 28Peregrine Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2014 29Peregrine Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2014 30Peregrine Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014 31

  11. Related Reports • Global Neurosurgery Market 2015-2019 • Active Pharmaceutical Ingredients (API) Market in India 2015-2019 • BrainStorm Cell Therapeutics Inc. (BCLI) - Financial and Strategic SWOT Analysis Review • Ampio Pharmaceuticals, Inc. (AMPE) - Financial and Strategic SWOT Analysis Review • MiMedx Group, Inc (MDXG) - Financial and Strategic SWOT Analysis Review

  12. Related Reports • Threshold Pharmaceuticals, Inc. (THLD) - Financial and Strategic SWOT Analysis Review • MEI Pharma, Inc. (MEIP) - Financial and Strategic SWOT Analysis Review • Titan Pharmaceuticals, Inc. (TTNP) - Financial and Strategic SWOT Analysis Review • RedHill Biopharma Ltd. (RDHL) - Financial and Strategic SWOT Analysis Review • Pharmaceuticals & Healthcare Market Research Reports

  13. Peregrine Pharmaceuticals, Inc. - Product Pipeline Review – 2014 Published: Oct 2014 | 44 Pages “Peregrine Pharmaceuticals, Inc. - Product Pipeline Review - 2014”report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Price

  14. Contact Us Office Office No. - 809, 8th Floor,B-Wing, Mahaavir Icon, Plot No.- 89 & 90, Sector-15,CBD-Belapur, Navi Mumbai – 400614, Maharashtra, India. Telefax No: +91 22 4127 6660 24/7 Online Support: +91 9987295242 General Inquiries : +91 - 22 2756 4953 You Can Visit http://www.aarkstore.com OR Mail us at contact@aarkstore.com Blog : http://www.aarkstore.com/blog/ Conference : http://conference.aarkstore.com/ News : http://www.aarkstore.com/news

More Related